[Skip to Navigation]
Views 936
Citations 0
Comment & Response
June 9, 2021

Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient

Author Affiliations
  • 1Lp(a)CARE, Minneapolis, Minnesota
JAMA Cardiol. 2021;6(9):1096-1097. doi:10.1001/jamacardio.2021.1592

To the Editor Trinder and colleagues1 conclude that LPA genetic risk score and measured lipoprotein(a) level provide comparable risk prediction for incident atherosclerotic cardiovascular disease (ASCVD) and provide improvement in risk discrimination beyond guideline-supported risk scores, which supports that lipoprotein(a) is a risk-enhancing factor.

Add or change institution